According to Emergen Research, the global antibody drug conjugates market size was USD 3.18 billion in 2020 and is expected to reach USD 20.01 billion in 2028 and register a revenue CAGR of 25.8% during the forecast period, 2021-2028.
Emergen Research has published its latest report titled “Antibody Drug Conjugates Market, By Technology (Cleavable Linker, Non-cleavable Linker, Linkerless), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Urothelial Cancer & Bladder Cancer, Lung Cancer, Brain Tumor, Others), By End-use (Hospitals & Clinics, Research Institutes, Others), and By Region, Forecast to 2028”
According to Emergen Research, the global antibody drug conjugates market size was USD 3.18 billion in 2020 and is expected to reach USD 20.01 billion in 2028 and register a revenue CAGR of 25.8% during the forecast period, 2021-2028.
Market Dynamics:
Rise in global geriatric population, increasing prevalence of different types of cancer worldwide, and increasing investments by government bodies in pharmaceutical research & development activities for more advanced cancer drugs and therapeutics are among the principal factors driving the global antibody drug conjugates market revenue growth. Antibody drug conjugates (ADCs) are generally used in cancer therapies and help increase the cell-killing potential of monoclonal antibodies. ADCs are made of an antibody drug, cytotoxic chemotherapy drug, and a linker. Other major advantages of these drugs are higher tumor selectivity, limited systemic exposure, and increased drug tolerability. Increasing preclinical research programs, rising number of clinical trials for new cancer therapeutics, growing emphasis of pharmaceutical companies on new drug discovery & development, and emergence of advanced antibody therapies are some of the other major factors driving revenue growth of the global antibody drug conjugates market significantly.
Click Here to Access Free sample PDF Copy of the Report@ https://www.emergenresearch.com/request-sample/754
COVID-19 Impact Analysis:
- Social distancing and restrictions severely disrupted businesses and operations
- Lockdowns caused disruptions in transportation and logistics
- Impacted manufacturing activities and mining operations globally
- Took a toll on economy of various countries
- Caused sudden and drastic downturn in economic activity
- Disrupted agriculture, fisheries, dairy, and other sectors
- Caused loss of employment and financial crisis
- Supply impacts were further compounded owing to reduced disposable income
- Emergence of variants continue to cause concerns and impact normal routines
Non-cleavable Linker Technology Segment Accounted for Largest Revenue Share in 2020:
Based on technology, the global antibody drug conjugates market is segmented into cleavable linker, non-cleavable linker, and linkerless technologies. The non-cleavable linker segment held the largest revenue share in the global market in 2020, mainly owing to factors such as increasing awareness of the advantages of non-cleavable linkers over cleavable linkers, such as increased plasma stability, greater therapeutic window, and higher stability and tolerability.
Blood Cancer Segment to Account for Fastest Revenue CAGR:
In terms of application, the global antibody drug conjugates market is segmented into blood cancer, brain tumor, ovarian cancer, breast cancer, lung cancer, and others. The blood cancer segment is expected to dominate other segments in terms of fastest revenue CAGR over the forecast period. Blood cancer is one of the most common types of cancer, mostly affecting older adults. Rising prevalence of blood cancer worldwide, increasing R&D activities for advanced and effective ADCs to treat the disease, increasing regulatory approvals for various newly developed ADCs, and development of new targeted therapies for blood cancer are key factors driving this segment’s growth.
North America Accounted for Largest Revenue Share in 2020:
Among regional markets, the North America antibody drug conjugates market accounted for the largest revenue share in the global market in 2020, owing to factors such as rising burden of cancer, growing cancer awareness among the population, ongoing new drug pipeline projects, and presence of major industry players in the region, including Pfizer, Inc., AstraZeneca, and Gilead Sciences, Inc., are among the major factors contributing to the North America market revenue growth.
Make Payment [Buy your Exclusive copy]@ https://www.emergenresearch.com/select-license/754
Major Companies in the Global Antibody Drug Conjugates Market Include:
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Ltd.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc
- Novartis AG
- AstraZeneca
- Gilead Sciences, Inc.
- Sanofi S.A.
- Astellas Pharma
- Seagen, Inc.
- Daiichi Sankyo Company Ltd.
- ADC Therapeutics
- Seattle Genetics Inc.
- Genentech Inc.
- Immunogen Inc.
- Immunomedics, Inc.
- Progenics Pharmaceuticals Inc.
- Bayer Healthcare Pharmaceuticals
- Agensys, Inc.
- Concortis Biotherapeutics
- Celldex Therapeutics Inc.
- Synthon Holding B.V.
For the purpose of this report, Emergen Research has segmented the global antibody drug conjugates market based on technology, application, end-use, and region:
Technology Outlook (Revenue, USD Billion; 2018-2028)
- Cleavable Linker
- Non-cleavable Linker
- Linkerless
Application Outlook (Revenue, USD Billion; 2018-2028)
- Blood Cancer
- Leukemia
- Lymphoma
- Multiple Myeloma
- Breast Cancer
- Ovarian Cancer
- Urothelial Cancer & Bladder Cancer
- Lung Cancer
- Brain Tumor
- Others
End-use Outlook (Revenue, USD Billion; 2018-2028)
- Hospitals & Clinics
- Research Institutes
- Others
Have a look at Report Description and Table of Contents of Market Report@ https://www.emergenresearch.com/industry-report/antibody-drug-conjugates-market
Region Outlook (Revenue, USD Billion; 2018-2028)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Turkey
- Rest of Middle East & Africa
Explore Reports offered by Emergen Research:
The global nutrigenomics market size reached USD 389.4 Million in 2020 and is expected to register a CAGR of 16.2% during the forecast period. Market revenue growth is primarily driven by increasing global burden of nutrition-related noncommunicable diseases.
The global Sanger sequencing services market size was significantly robust in 2020 and is expected to register steady revenue CAGR over the forecast period. Increasing advancements in sequencing techniques, benefits of Sanger sequencing, and rising investments to accelerate R&D activities in genomics are key factors expected to drive market revenue growth over the forecast period. In addition, increasing application scope of Sangers sequencing technique has boosted deployment of this procedure and is another key factor expected to further contribute to revenue growth of the market going ahead.
The global whole exome sequencing (WES) market size was significantly robust in 2020 and is expected to register a steady revenue CAGR during the forecast period. Rapid adoption of cutting-edge technologies, and rising awareness regarding whole exome sequencing technology are some key factors expected to drive market revenue growth over the forecast period.
The global health data archiving market size is expected to reach USD 9.28 Billion in 2028 and register a revenue CAGR of 14.1% during the forecast period. Increasing volume of digital data and rapid deployment of cloud-based storage solutions are key factors driving global health data archiving market revenue growth.
The global gel documentation system market size reached USD 291.5 Million in 2020 and is expected to register a revenue CAGR of 3.6% during the forecast period. Major factors driving gel documentation system market revenue growth are rising prevalence of infectious diseases and genetic disorders, and rapid developments and advancements across pharmaceutical and biotechnological industries globally.
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
Full Press Release@ https://www.emergenresearch.com/press-release/global-antibody-drug-conjugates-market